Theranostics has crossed the chasm.
The shorthand we keep using inside Bracken: the radiopharma decade is no longer a thesis, it's an operating reality. Pivotal trial readouts in prostate cancer have validated the playbook, and oncology programs in breast, lung, and rare tumors are following the same template.
The interesting questions for 2026 are no longer scientific. They are operational, regulatory, and commercial.
The drug pipeline: lutetium, actinium, copper, and beyond.
Lu-177 still anchors the conversation. Ac-225 programs are no longer speculative; multiple sponsors have moved beyond proof of concept. Cu-64 and Pb-212 are the isotopes most likely to surprise on the upside in 2026.
The supply chain bottleneck: isotopes, reactors, cyclotrons.
Mo-99 supply was the warning shot. Lu-177 is the live wire. Ac-225 is the next constraint. The teams that planned isotope sourcing two years ago are in dramatically better position than the ones starting now.
The CDMO/CMO build-out.
Capital is flowing into radiopharma CDMOs at a pace that will drive consolidation within 24 months. The differentiator isn't square footage, it's the mix of GMP radiochemistry, regulatory sophistication, and clinical-trial infrastructure.
Imaging endpoints and biomarkers, the Bracken throughline.
This is the section we'll write longest. Imaging endpoints are how radiopharma trials become regulator-ready. Dosimetry, central reading, and response criteria are not afterthoughts; they shape go/no-go.
Most teams underestimate the operational lift of a multicenter imaging trial in radioligand therapy. Bracken has run the playbook enough times to see the same three failure modes: site readiness, central-read standardization, and dosimetry harmonization.
The encouraging news is that the field has converged on a tractable set of imaging endpoints. The remaining question is execution discipline.
Regulatory inflection points.
FDA's evolving expectations on dosimetry, EMA's posture on theranostic pairs, and PMDA's growing engagement on radioligand therapy are all worth monitoring. Sponsors who treat regulatory strategy as a phase-zero workstream will see fewer surprises in phase III.
AI in nuclear medicine.
The honest read: lots of demos, few clinically deployed workflows. The question for 2026 is which AI tools cross the line from interesting to trusted in regulated reading workflows.
What to watch in 2026 and 2027.
Six things on Bracken's watchlist: an Ac-225 pivotal readout, a major CDMO capacity announcement, FDA dosimetry guidance, two strategic acquisitions in imaging endpoints, the first credible AI reading workflow at scale, and a quiet expansion into Cu-64.